Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 285 drug-target rows in SSL view, for TSG = SESN2.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib SESN2 KDR 6
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus SESN2 MTOR 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SESN2 KDR 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) SESN2 KDR 3
abemaciclib SESN2 CDK6 6
abemaciclib SESN2 CDK4 6
gemcitabine SESN2 RRM1 6
nintedanib SESN2 KDR 6
pazopanib SESN2 KDR 6
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SESN2 RRM1 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SESN2 KDR 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SESN2 KDR 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SESN2 CDK6 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SESN2 CDK4 2
alvocidib, paclitaxel SESN2 CDK6 2
alvocidib, paclitaxel SESN2 CDK4 2
alvocidib, paclitaxel SESN2 CDK2 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SESN2 RRM1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 SESN2 KDR 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib SESN2 KDR 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab SESN2 RRM1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab SESN2 CDK6 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab SESN2 CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib SESN2 KDR 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SESN2 KDR 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine SESN2 RRM1 2
lenvatinib, pembrolizumab SESN2 KDR 2
nintedanib, pembrolizumab SESN2 KDR 2
pembrolizumab, belzutifan, lenvatinib SESN2 KDR 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SESN2 KDR 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SESN2 RRM1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SESN2 KDR 2
ramucirumab, paclitaxel SESN2 KDR 2
sorafenib, administered orally, ct/mri SESN2 KDR 2
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab SESN2 RRM1 2
temsirolimus SESN2 MTOR 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy SESN2 KDR 2
axitinib SESN2 KDR 6
cabozantinib SESN2 KDR 6
everolimus SESN2 MTOR 6
palbociclib SESN2 CDK6 6
palbociclib SESN2 CDK4 6
regorafenib SESN2 KDR 6
ribociclib SESN2 CDK6 6
ribociclib SESN2 CDK4 6
sorafenib SESN2 KDR 6
trilaciclib SESN2 CDK6 6
trilaciclib SESN2 CDK4 6
ramucirumab SESN2 KDR 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) SESN2 KDR 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin SESN2 RRM1 1
abemaciclib, abemaciclib SESN2 CDK6 1
abemaciclib, abemaciclib SESN2 CDK4 1
abemaciclib, bevacizumab SESN2 CDK6 1
abemaciclib, bevacizumab SESN2 CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf SESN2 CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf SESN2 CDK4 1
abemaciclib, ly3214996 SESN2 CDK6 1
abemaciclib, ly3214996 SESN2 CDK4 1
abemaciclib, surgery SESN2 CDK6 1
abemaciclib, surgery SESN2 CDK4 1
aee788, everolimus SESN2 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SESN2 CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SESN2 CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SESN2 MTOR 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel SESN2 KDR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SESN2 CDK6 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SESN2 CDK4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SESN2 MTOR 1
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SESN2 KDR 1
atezolizumab, cabozantinib SESN2 KDR 1
axitinib, avelumab SESN2 KDR 1
axitinib, axitinib plus lomustine SESN2 KDR 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab SESN2 RRM1 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus SESN2 MTOR 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil SESN2 KDR 1
bevacizumab, cediranib, cediranib maleate, olaparib SESN2 KDR 1
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib SESN2 CDK6 1
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib SESN2 CDK4 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib SESN2 KDR 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging SESN2 KDR 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, palbociclib SESN2 CDK6 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, palbociclib SESN2 CDK4 1
biospecimen collection, computed tomography, magnetic resonance imaging, nivolumab, paclitaxel, questionnaire administration, ramucirumab SESN2 KDR 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography SESN2 KDR 1
blu-222, carboplatin, ribociclib, fulvestrant SESN2 CDK6 1
blu-222, carboplatin, ribociclib, fulvestrant SESN2 CDK4 1
busulfan, anti-thymocyte globulin, fludarabine, cyclosporine, mycophenolate mofetil SESN2 RRM1 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SESN2 KDR 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SESN2 CDK6 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SESN2 CDK4 1
cabozantinib, durvalumab, tremelimumab SESN2 KDR 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab SESN2 KDR 1
cediranib, cediranib, lomustine chemotherapy, placebo cediranib SESN2 KDR 1
cediranib, lomustine SESN2 KDR 1
chemotherapy, cladribine, radiation therapy SESN2 RRM1 1
chemotherapy, cladribine, radiation therapy SESN2 POLE 1
chemotherapy, hydroxyurea, pentoxifylline, radiation therapy SESN2 RRM1 1
cisplatin, pemetrexed disodium, sorafenib SESN2 KDR 1
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study SESN2 MTOR 1
conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus SESN2 MTOR 1
crenolanib, ramucirumab, paclitaxel SESN2 KDR 1
cytoreductive surgery, perifosine, temsirolimus SESN2 MTOR 1
dimethyl fumarate, temozolomide, radiation therapy SESN2 RELA 1
docetaxel, laboratory biomarker analysis, palbociclib SESN2 CDK6 1
docetaxel, laboratory biomarker analysis, palbociclib SESN2 CDK4 1
e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide SESN2 RRM1 1
epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide SESN2 RRM1 1
erdafitinib SESN2 KDR 1
erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study SESN2 MTOR 1
everolimus, archival tissue analysis SESN2 MTOR 1
everolimus, gefitinib SESN2 MTOR 1
everolimus, laboratory biomarker analysis SESN2 MTOR 1
everolimus, lde 225 SESN2 MTOR 1
everolimus, placebo SESN2 MTOR 1
everolimus, sorafenib SESN2 KDR 1
everolimus, sorafenib SESN2 MTOR 1
everolimus, temozolomide, microarray analysis, immunohistochemistry staining method SESN2 MTOR 1
everolimus, temozolomide, radiation SESN2 MTOR 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel SESN2 KDR 1
fludarabine, cyclophosphamide, ima101 product, recombinant human interleukin-2, imadetect, atezolizumab SESN2 RRM1 1
fluorouracil, leucovorin calcium, oxaliplatin, everolimus, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis SESN2 MTOR 1
fruquintinib, sintilimab SESN2 KDR 1
fruquintinib, tislelizumab, radiotherapy SESN2 KDR 1
gallium maltolate SESN2 RRM1 1
gemcitabine, oxaliplatin, dexamethasone, floxuridine (fudr), implanted medical device SESN2 RRM1 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim SESN2 RRM1 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim SESN2 CDK6 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim SESN2 CDK4 1
gemcitabine, vinorelbine, cisplatin, etoposide, carboplatin SESN2 RRM1 1
hydroxyurea, imatinib mesylate SESN2 RRM1 1
hydroxyurea, imatinib mesylate, vatalanib SESN2 RRM1 1
hydroxyurea, imatinib mesylate, vatalanib SESN2 KDR 1
ibrutinib, fludarabine SESN2 RRM1 1
imatinib mesylate, hydroxyurea SESN2 RRM1 1
imt-009, fruquintinib SESN2 KDR 1
irinotecan, ramucirumab, blood for angiome profiling, blood for cfdna SESN2 KDR 1
laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery SESN2 MTOR 1
laboratory biomarker analysis, pharmacological study, temsirolimus, trebananib SESN2 MTOR 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil SESN2 KDR 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil SESN2 MTOR 1
lenvatinib, bevacizumab SESN2 KDR 1
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SESN2 KDR 1
ly3410738, gemcitabine, cisplatin, durvalumab SESN2 RRM1 1
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SESN2 RRM1 1
metformin xr, delayed metformin, sirolimus SESN2 MTOR 1
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed SESN2 RRM1 1
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SESN2 KDR 1
mycophenolate mofetil, tacrolimus, post-transplant cyclophosphamide, total body irradiation, hematopoietic cell transplant, jsp191, cyclophosphamide, fludarabine SESN2 RRM1 1
nab-paclitaxel, gemcitabine SESN2 RRM1 1
nimotuzumab, gemcitabine, carboplatin, surgery SESN2 RRM1 1
nivolumab, cabozantinib SESN2 KDR 1
olaparib, ramucirumab SESN2 KDR 1
olaratumab, ramucirumab SESN2 KDR 1
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu SESN2 RRM1 1
oxaliplatin, sorafenib SESN2 KDR 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) SESN2 KDR 1
paclitaxel, quality-of-life assessment, ramucirumab, trifluridine and tipiracil hydrochloride SESN2 KDR 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) SESN2 MTOR 1
palbociclib, afatinib SESN2 CDK6 1
palbociclib, afatinib SESN2 CDK4 1
palbociclib, gedatolisib SESN2 CDK6 1
palbociclib, gedatolisib SESN2 CDK4 1
pasireotide lar, everolimus, pasireotide lar and everolimus combination SESN2 MTOR 1
pazopanib, 5-fu, oxaliplatin, leukovorin (flo) SESN2 KDR 1
pazopanib, lapatinib SESN2 KDR 1
pazopanib, placebo SESN2 KDR 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel SESN2 KDR 1
pembrolizumab, lenvatinib SESN2 KDR 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel SESN2 KDR 1
pentostatin, sirolimus, cyclophosphamide, allogeneic hematopoietic stem cell transplant (hsct), th2 rapa cells, donor lymphocyte harvest, induction therapy, gvhd prophylaxis, donor hematopoietic stem cell harvest SESN2 MTOR 1
pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, temsirolimus, temozolomide SESN2 MTOR 1
ponatinib SESN2 KDR 1
radiation therapy, temozolomide, bevacizumab, bevacizumab, everolimus SESN2 MTOR 1
radiation therapy, temozolomide, sorafenib SESN2 KDR 1
ramucirumab, capecitabine, cisplatin, placebo, fluorouracil SESN2 KDR 1
ramucirumab, paclitaxel, mk-2870 SESN2 KDR 1
ramucirumab, paclitaxel, placebo SESN2 KDR 1
ramucirumab, placebo, oxaliplatin, leucovorin, 5-fluorouracil SESN2 KDR 1
ramucirumab, placebo, s-1, oxaliplatin, paclitaxel SESN2 KDR 1
regorafenib, laboratory biomarker analysis SESN2 KDR 1
regorafenib, lomustine SESN2 KDR 1
regorafenib, nivolumab, capeox, folfox regimen SESN2 KDR 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil SESN2 KDR 1
regorafenib, temozolomide SESN2 KDR 1
ribociclib, everolimus SESN2 CDK6 1
ribociclib, everolimus SESN2 CDK4 1
ribociclib, everolimus SESN2 MTOR 1
ridaforolimus, mk-0752, mk-2206 SESN2 MTOR 1
rucaparib, ramucirumab, nivolumab SESN2 KDR 1
semaxanib SESN2 KDR 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome SESN2 KDR 1
sirolimus, placebo SESN2 MTOR 1
sirolimus, vandetanib SESN2 MTOR 1
sorafenib tosylate, erlotinib hydrochloride, tipifarnib, temsirolimus SESN2 MTOR 1
sra737, gemcitabine, cisplatin, sra737, gemcitabine SESN2 RRM1 1
sunitinib, placebo SESN2 KDR 1
sunitinib, radiation SESN2 KDR 1
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel SESN2 RRM1 1
tacrolimus, methotrexate, sirolimus SESN2 MTOR 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.